Repligen To Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities With Market Leading Biopreservation Media - RGEN News | RalliesRepligen To Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities With Market Leading Biopreservation Media
R
RGEN• Repligen to acquire BioLife Solutions
- Repligen to acquire BioLife Solutions, expanding its cell therapy capabilities with market leading biopreservation media
- BioLife Solutions - Repligen to buy BioLife for $1.50 billion enterprise value, 64% stock, 36% cash
- BioLife Solutions - Stockholders to receive $31 per share in cash and Repligen stock
- BioLife Solutions - Stockholders to receive $11.25 cash and 0.1442 Repligen shares per BioLife share
- BioLife Solutions - Deal expected to be accretive to Repligen's adjusted EPS by $0.05 in year one, $0.25 in year two
- BioLife Solutions - Repligen expects at least $20 million synergies in year one, $30 million in year two
- BioLife Solutions - Expects preliminary Q2 revenue of $28.50 million, up 21% from Q2 2025
- BioLife Solutions - Preliminary Q2 revenue growth 21% year-over-year
- BioLife Solutions - Repligen preliminary Q2 reported revenue growth 12%, organic revenue growth 13%
GCBC
•
